Idiopathic generalised epilepsy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:26 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Idiopathic generalised epilepsy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy https://clinicaltrials.eu/trial/study-on-bhv-7000-for-patients-with-generalized-tonic-clonic-seizures-in-idiopathic-generalized-epilepsy/ Wed, 29 Apr 2026 14:58:34 +0000 https://clinicaltrials.eu/trial/study-on-bhv-7000-for-patients-with-generalized-tonic-clonic-seizures-in-idiopathic-generalized-epilepsy/ This clinical trial is focused on studying Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures. The trial will evaluate a treatment called BHV-7000, which is a prolonged-release tablet developed by Biohaven Therapeutics Ltd. The purpose of the study is to compare the effectiveness of BHV-7000 to a placebo when used as an additional therapy for people with this type of epilepsy.

Participants in the study will receive either the BHV-7000 tablet or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The trial will include an open-label extension, which means that after the initial phase, all participants may have the opportunity to receive BHV-7000 if they choose to continue. The study will last for a period of up to 72 weeks.

The main goal is to observe the time it takes for participants to experience a second day with a generalized tonic-clonic seizure during the double-blind phase. Additionally, the study will assess the safety and tolerability of BHV-7000 by monitoring any side effects or adverse events that occur. This trial aims to provide valuable information on the potential benefits and risks of using BHV-7000 as a treatment option for individuals with this form of epilepsy.

]]>